Clinical Trial Update: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study [Phase 4]

View source ↗

Summary

Phase 4 post-marketing requirement study for TEPEZZA (teprotumumab-trbw) in Thyroid Eye Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• TEPEZZA (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Thyroid Eye Disease | Phase 4 | Status: COMPLETED